
|Videos|March 14, 2017
Access to High Cost Drugs Remains a Challenge in Specialty
Author(s)Lauren Santye, Assistant Editor
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
3
Targeting CSF1R in TGCT: Evaluating the Evidence and Empowering Pharmacist-Led Care
4
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
5










































































































